Varian restructures its business divisions
This article was originally published in Clinica
Varian Associates is to separate its brachytherapy business from its oncology systems division and will establish dedicated research, marketing, sales and support resources for the new business unit, to be known as Varian Brachytherapy.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.